Skip to main content
Journal cover image

Carboplatin dosing in the treatment of ovarian cancer: An NRG oncology group study.

Publication ,  Journal Article
Praiss, AM; Miller, A; Smith, J; Lichtman, SM; Bookman, M; Aghajanian, C; Sabbatini, P; Backes, F; Cohn, DE; Argenta, P; Friedlander, M ...
Published in: Gynecol Oncol
July 2023

OBJECTIVE: To determine the effects of using National Comprehensive Cancer Network (NCCN) guidelines to estimate renal function on carboplatin dosing and explore adverse effects associated with a more accurate estimation of lower creatinine clearance (CrCl). METHODS: Retrospective data were obtained for 3830 of 4312 patients treated on GOG182 (NCT00011986)-a phase III trial of platinum-based chemotherapy for advanced-stage ovarian cancer. Carboplatin dose per patient on GOG182 was determined using the Jelliffe formula. We recalculated CrCl to determine dosing using Modification of Diet in Renal Disease (MDRD) and Cockcroft-Gault (with/without NCCN recommended modifications) formulas. Associations between baseline CrCl and toxicity were described using the area under the receiver operating characteristic curve (AUC). Sensitivity and positive predictive values described the model's ability to discriminate between subjects with/without the adverse event. RESULTS: AUC statistics (range, 0.52-0.64) showed log(CrClJelliffe) was not a good predictor of grade ≥3 adverse events (anemia, thrombocytopenia, febrile neutropenia, auditory, renal, metabolic, neurologic). Of 3830 patients, 628 (16%) had CrCl <60 mL/min. Positive predictive values for adverse events ranged from 1.8%-15%. Using the Cockcroft-Gault, Cockcroft-Gault with NCCN modifications, and MDRD (instead of Jelliffe) formulas to estimate renal function resulted in a >10% decrease in carboplatin dosing in 16%, 32%, and 5.2% of patients, respectively, and a >10% increase in carboplatin dosing in 41%, 9.6% and 12% of patients, respectively. CONCLUSION: The formula used to estimate CrCl affects carboplatin dosing. Estimated CrCl <60 mL/min (by Jelliffe) did not accurately predict adverse events. Efforts continue to better predict renal function. Endorsing National Cancer Institute initiatives to broaden study eligibility, our data do not support a minimum threshold CrCl <60 mL/min as an exclusion criterion from clinical trials.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Gynecol Oncol

DOI

EISSN

1095-6859

Publication Date

July 2023

Volume

174

Start / End Page

213 / 223

Location

United States

Related Subject Headings

  • Retrospective Studies
  • Ovarian Neoplasms
  • Oncology & Carcinogenesis
  • Kidney Function Tests
  • Humans
  • Glomerular Filtration Rate
  • Female
  • Creatinine
  • Carboplatin
  • 3215 Reproductive medicine
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Praiss, A. M., Miller, A., Smith, J., Lichtman, S. M., Bookman, M., Aghajanian, C., … O’Cearbhaill, R. E. (2023). Carboplatin dosing in the treatment of ovarian cancer: An NRG oncology group study. Gynecol Oncol, 174, 213–223. https://doi.org/10.1016/j.ygyno.2023.05.013
Praiss, Aaron M., Austin Miller, Judith Smith, Stuart M. Lichtman, Michael Bookman, Carol Aghajanian, Paul Sabbatini, et al. “Carboplatin dosing in the treatment of ovarian cancer: An NRG oncology group study.Gynecol Oncol 174 (July 2023): 213–23. https://doi.org/10.1016/j.ygyno.2023.05.013.
Praiss AM, Miller A, Smith J, Lichtman SM, Bookman M, Aghajanian C, et al. Carboplatin dosing in the treatment of ovarian cancer: An NRG oncology group study. Gynecol Oncol. 2023 Jul;174:213–23.
Praiss, Aaron M., et al. “Carboplatin dosing in the treatment of ovarian cancer: An NRG oncology group study.Gynecol Oncol, vol. 174, July 2023, pp. 213–23. Pubmed, doi:10.1016/j.ygyno.2023.05.013.
Praiss AM, Miller A, Smith J, Lichtman SM, Bookman M, Aghajanian C, Sabbatini P, Backes F, Cohn DE, Argenta P, Friedlander M, Goodheart MJ, Mutch DG, Gershenson DM, Tewari KS, Wenham RM, Wahner Hendrickson AE, Lee RB, Gray H, Secord AA, Van Le L, O’Cearbhaill RE. Carboplatin dosing in the treatment of ovarian cancer: An NRG oncology group study. Gynecol Oncol. 2023 Jul;174:213–223.
Journal cover image

Published In

Gynecol Oncol

DOI

EISSN

1095-6859

Publication Date

July 2023

Volume

174

Start / End Page

213 / 223

Location

United States

Related Subject Headings

  • Retrospective Studies
  • Ovarian Neoplasms
  • Oncology & Carcinogenesis
  • Kidney Function Tests
  • Humans
  • Glomerular Filtration Rate
  • Female
  • Creatinine
  • Carboplatin
  • 3215 Reproductive medicine